Month: December 2012

Technology Cellanyx is developing a biopsy-on-a-chip technology focused on tumor cell behavior by analyzing multiple phenotypic, biochemical and physical markers of individual living cells cultured from fresh biopsy samples. The company’s suite of biomarkers represent multiple biological pathways and morphological, [...]

 Prostate Cancer Diagnostic Cellanyx’s lead test in development is a diagnostic to stratify the risk of local tumor spread and metastasis in men with prostate cancer - low and intermediate risk Gleason grades. The test provides a quantitative, actionable assessment [...]

About Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessments of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical [...]